See today's BioWorld
To read the full story, subscribe or sign in.

Third ADC candidate with Synaffix’s tech enters clinic as Miracogen kicks off phase I

Oct. 8, 2021
By David Ho
It looks like Shanghai Miracogen Inc.’s antibody-drug conjugate (ADC) partnership with Synaffix BV is paying off as MRG-004A, an ADC designed to treat solid tumors, has entered a U.S. phase I/II trial to treat solid tumors.
BioWorld Clinical Cancer Antibody-drug conjugate China